Integris Wealth Management LLC Raises Position in Johnson & Johnson (NYSE:JNJ)

Integris Wealth Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 16.3% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,691 shares of the company’s stock after purchasing an additional 1,216 shares during the period. Johnson & Johnson makes up approximately 0.4% of Integris Wealth Management LLC’s portfolio, making the stock its 28th largest position. Integris Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,270,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Alliance Wealth Advisors LLC UT grew its position in shares of Johnson & Johnson by 1.4% in the 4th quarter. Alliance Wealth Advisors LLC UT now owns 4,714 shares of the company’s stock valued at $739,000 after acquiring an additional 64 shares during the period. Carolinas Wealth Consulting LLC raised its stake in Johnson & Johnson by 0.4% in the fourth quarter. Carolinas Wealth Consulting LLC now owns 16,861 shares of the company’s stock valued at $2,643,000 after buying an additional 64 shares during the period. Epic Trust Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 3.6% in the second quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company’s stock valued at $268,000 after buying an additional 64 shares during the last quarter. Verity Asset Management Inc. increased its holdings in shares of Johnson & Johnson by 2.0% during the 4th quarter. Verity Asset Management Inc. now owns 3,268 shares of the company’s stock worth $512,000 after acquiring an additional 65 shares during the last quarter. Finally, Forza Wealth Management LLC raised its stake in Johnson & Johnson by 0.8% in the 2nd quarter. Forza Wealth Management LLC now owns 8,742 shares of the company’s stock valued at $1,278,000 after acquiring an additional 66 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. The Goldman Sachs Group decreased their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. TD Securities cut their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, Morgan Stanley lifted their price target on shares of Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Trading Up 0.2 %

Shares of JNJ stock traded up $0.30 during mid-day trading on Friday, reaching $159.39. 5,012,774 shares of the stock traded hands, compared to its average volume of 7,341,345. The stock’s fifty day simple moving average is $152.38 and its two-hundred day simple moving average is $153.06. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.39. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company has a market cap of $383.60 billion, a price-to-earnings ratio of 9.94, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same quarter in the previous year, the business earned $2.80 earnings per share. Johnson & Johnson’s revenue was up 4.3% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.11%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.